Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    ALX Oncology Inc.

    NASDAQ: ALXO · Real-Time Price · USD
    0.49
    -0.04 (-7.83%)
    At close: Jun 17, 2025, 3:59 PM

    ALX Oncology Statistics

    Share Statistics

    ALX Oncology has 53.44M shares outstanding. The number of shares has increased by 2.46% in one year.

    Shares Outstanding

    n/a
    		 53.44M

    Shares Change (YoY)

    n/a
    		 2.46%

    Shares Change (QoQ)

    n/a
    		 1.22%

    Owned by Institutions (%)

    n/a
    		 77.94%

    Shares Floating

    n/a
    		 33.8M

    Failed to Deliver (FTD) Shares

    n/a
    		 298

    FTD / Avg. Volume

    n/a
    		 0.06%

    Short Selling Information

    The latest short interest is 5.69M, so 10.65% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 5.69M

    Short % of Shares Out

    n/a
    		 10.65%

    Short % of Float

    n/a
    		 16.96%

    Short Ratio (days to cover)

    n/a
    		 14.36

    Valuation Ratios

    The PE ratio is -0.65 and the forward PE ratio is -0.4. ALX Oncology's PEG ratio is 0.02.

    PE Ratio

    n/a
    		 -0.65

    Forward PE

    n/a
    		 -0.4

    PS Ratio

    n/a
    		 0

    Forward PS

    n/a
    		 0.2

    PB Ratio

    n/a
    		 0.77

    P/FCF Ratio

    n/a
    		 -0.71

    PEG Ratio

    n/a
    		 0.02
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for ALX Oncology.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 7.26, with a Debt / Equity ratio of 0.09.

    Current Ratio

    n/a
    		 7.26

    Quick Ratio

    n/a
    		 7.26

    Debt / Equity

    n/a
    		 0.09

    Debt / EBITDA

    n/a
    		 -0.07

    Debt / FCF

    n/a
    		 -0.08

    Interest Coverage

    n/a
    		 -82.4

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 $-2,074,615.38

    Employee Count

    n/a
    		 65

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by -92.82% in the last 52 weeks. The beta is 1.16, so ALX Oncology's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.16

    52-Week Price Change

    n/a
    		 -92.82%

    50-Day Moving Average

    n/a
    		 0.51

    200-Day Moving Average

    n/a
    		 1.23

    Relative Strength Index (RSI)

    n/a
    		 51.81

    Average Volume (20 Days)

    n/a
    		 489,420

    Income Statement

    Revenue

    n/a
    		 n/a

    Gross Profit

    n/a
    		 n/a

    Operating Income

    n/a
    		 -142.47M

    Net Income

    n/a
    		 -134.85M

    EBITDA

    n/a
    		 -132.25M

    EBIT

    n/a
    		 -133.12M

    Earnings Per Share (EPS)

    n/a
    		 -2.58
    Full Income Statement

    Balance Sheet

    The company has 17.57M in cash and 9.9M in debt, giving a net cash position of 7.66M.

    Cash & Cash Equivalents

    n/a
    		 17.57M

    Total Debt

    n/a
    		 9.9M

    Net Cash

    n/a
    		 7.66M

    Retained Earnings

    n/a
    		 -621.12M

    Total Assets

    n/a
    		 120.9M

    Working Capital

    n/a
    		 83.79M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -121.91M and capital expenditures -447K, giving a free cash flow of -122.36M.

    Operating Cash Flow

    n/a
    		 -121.91M

    Capital Expenditures

    n/a
    		 -447K

    Free Cash Flow

    n/a
    		 -122.36M

    FCF Per Share

    n/a
    		 -2.35
    Full Cash Flow Statement

    Margins

    Gross Margin

    n/a
    		 n/a

    Operating Margin

    n/a
    		 n/a

    Pretax Margin

    n/a
    		 n/a

    Profit Margin

    n/a
    		 n/a

    EBITDA Margin

    n/a
    		 n/a

    EBIT Margin

    n/a
    		 n/a

    FCF Margin

    n/a
    		 n/a

    Dividends & Yields

    ALXO does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for ALXO is $1.75, which is 230.2% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $1.75

    Price Target Difference

    n/a
    		 230.2%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 6
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -9.82

    Piotroski F-Score

    n/a
    		 3

    Add to Watchlist